Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. - Wikidata - awgldk - TriplyDB

Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder.

Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder.

http://www.wikidata.org/entity/Q34662955

about

European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials The use of antidepressants to treat attention deficit hyperactivity disorder in adults.A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder Methylphenidate significantly improves declarative memory functioning of adults with ADHD.Non-stimulant treatments for ADHD.Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: a prospective long-term open-label study.Adult attention deficit hyperactivity disorder.An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults Double-blind controlled trial of venlafaxine for treatment of adults with attention deficit/hyperactivity disorder.Non-stimulant treatment for attention deficit hyperactivity disorder.Treatment of attention deficit hyperactivity disorder in adults.Attention deficit hyperactivity disorder (ADHD) and substance use disorders.Cognitive behavioral therapy vs relaxation with educational support for medication-treated adults with ADHD and persistent symptoms: a randomized controlled trial.Assessment and management of attention-deficit hyperactivity disorder in adults.The utility of rat models of impulsivity in developing pharmacotherapies for impulse control disorders.The premonitory urge to tic: measurement, characteristics, and correlates in older adolescents and adults.Pharmacotherapy of adult ADHD.Attention deficit disorder in adults. Management in primary care.The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.Adult ADHD and substance abuse: diagnostic and treatment issues.DRD4 and DAT1 in ADHD: Functional neurobiology to pharmacogenetics.Pharmacological treatment of attention-deficit/hyperactivity disorder in adults.Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD).Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology.Treatment of adult ADHD: is current knowledge useful to clinicians?ADHD in adults: a review of the literature.ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines.Once-daily medications for the pharmacological management of ADHD in adults Comorbidity and its impact in adult patients with attention-deficit/hyperactivity disorder: a primary care perspective.Pharmacotherapy of adult attention deficit hyperactivity disorder (ADHD): a meta-analysis.Recognizing ADHD in adults with comorbid mood disorders: implications for identification and management.A neurochemical yin and yang: does serotonin activate and norepinephrine deactivate the prefrontal cortex?A retrospective study of amitriptyline in youth with autism spectrum disorders.Alternative pharmacological strategies for adult ADHD treatment: a systematic review.Adult ADHD: A new disease?Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses.Neurobehavioural deficits associated with apoptotic neurodegeneration and vulnerability for ADHD.

P2860

Q21260332-6D9DBABF-613B-4875-8950-6DF47C416969 Q28236140-9DFC7AE4-7196-45F9-A339-A92B685DADB1 Q28246506-75C87D91-2AF0-4C77-AD4E-BAF75AC8CA86 Q28255609-096F1B55-F213-486E-BF4A-F9536F2C6058 Q30482547-BA5D0DB4-68FA-4A06-958B-0A0433CF0BAE Q34041736-FE9D73CF-227D-429F-B170-6C322D247BA9 Q34118011-434277D8-1E3A-43FA-A794-A9602A208106 Q34120068-29003076-B472-479B-8221-97112979D052 Q34172933-56C30671-A7CB-4B76-BEF6-DFAC5F311EA3 Q34200066-255742BC-32E3-4D4F-AF62-73D0F6028F68 Q34220004-F76A6179-BBBE-445D-8C1C-94F9471C2CD2 Q34247801-EB21A686-7509-4192-87F0-5AD9C1C0EC30 Q34396669-6BED32DC-7917-4530-9755-E43811CE0144 Q34413877-F7792D26-B2DF-4DA7-AF41-ED6003D566A8 Q34438018-93DAA8D2-1F15-463E-B308-68D79B1F20C8 Q34622772-AA097830-D242-49A4-A3F6-A081577A3E9C Q34995011-C850AAF0-FED9-44A1-A5B1-DE1A34A884DC Q35589965-7EAB7218-38F7-4D4C-AC01-B762997A7104 Q35652623-DB097F2B-FF98-4C7A-BFB6-C0C83B2ADDE3 Q36050450-7332E407-B5FE-49A8-B616-E135BF8777EB Q36054773-1487A382-1ACE-4132-B1C4-98D3558B34B9 Q36082025-34ECD350-D795-4190-B656-015EC90308EF Q36311022-5943F65C-5F7C-4207-9E1B-0F5A850BD8A1 Q36441473-BBCF19C9-9637-4427-B681-C8C08B9AE832 Q36491834-6E1797E9-43F3-4298-BBD7-4BF32439BF5F Q36594945-0ED149A2-39D9-4452-9116-F068F9F70703 Q36648476-3ED96DEB-9774-4E70-A3EF-6A1EAF7C255B Q36836781-675AB8AE-CF6A-4509-8E95-332A738D9C47 Q37038168-31DEB523-83A7-4D63-8ECD-799D9ECA61F3 Q37056071-8DA3233A-9E13-4E01-8235-240D67268F48 Q37230351-52AC33FC-4024-41A5-A787-2E7152949F4E Q37505871-AF60A3FE-3D75-4AC7-A6CE-F30A6F02A053 Q37542382-F3757D8F-5FBF-4F2C-9152-CD9A8AD50357 Q37612683-E055B99B-71E8-487C-846C-F392DFBCDFE1 Q37729903-F3D8B92D-5770-437C-AB9C-C34D8D2C43BA Q38058418-7F7F7CCF-6220-4E69-A74A-190342E1F841 Q38676199-6D423BCA-91A1-4E12-8550-C6D48024861C Q38799949-B43928C8-3197-44FF-919F-8190D70548F2 Q39213619-52922F41-85EA-47FE-9F0A-080CEEB442B2 Q42472653-F25C634E-1EA9-4749-90BB-CF03CDFC229F

P2860

Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder.

http://www.wikidata.org/entity/Q34662955

description

1996 nî lūn-bûn

@nan

1996 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

Six-week, double-blind, placeb ...... eficit hyperactivity disorder.

@ast

Six-week, double-blind, placeb ...... eficit hyperactivity disorder.

@en

Six-week, double-blind, placeb ...... eficit hyperactivity disorder.

@nl

type

label

Six-week, double-blind, placeb ...... eficit hyperactivity disorder.

@ast

Six-week, double-blind, placeb ...... eficit hyperactivity disorder.

@en

Six-week, double-blind, placeb ...... eficit hyperactivity disorder.

@nl

prefLabel

Six-week, double-blind, placeb ...... eficit hyperactivity disorder.

@ast

Six-week, double-blind, placeb ...... eficit hyperactivity disorder.

@en

Six-week, double-blind, placeb ...... eficit hyperactivity disorder.

@nl

P1433

Q34662955-174100E0-65F8-4604-9DD9-31147FE2E1FE

P1476

Q34662955-1FF08545-20E8-44E4-B513-4070A1CF7BA5

P2093

Q34662955-259B1356-0FFA-4DBD-8EDB-67A9E82C9E4B

Q34662955-592BFE4A-78C1-4F87-B992-5DAF95FE873E

Q34662955-9AD399FB-E252-4ED4-BF73-842BCA44692C

Q34662955-B1EB7FD3-E46C-4300-B563-E1427E3501B0

Q34662955-B5417BB9-DE29-41D1-BFAE-7990A7D179CD

Q34662955-B7F423EF-B39A-4171-A479-5A3F2766DBDC

Q34662955-F3ECF975-350E-4F0B-A104-C948531AFF31

Q34662955-F8CE1136-D61B-4F56-8E58-65A753ECF500

Q34662955-F97D78F6-6EA9-44AF-951A-0E6F82514387

P304

Q34662955-3FC5805B-F32C-4B61-B973-610F187EC025

P31

Q34662955-2FB39A0E-42E9-4DAD-9C58-77DAE6FFD27E

P356

Q34662955-58D32C4F-F213-43C1-A6CB-A01AC6679104

P407

Q34662955-125434B8-ABE9-46A5-B004-1C4AC5A6A6E9

P433

Q34662955-BC3739EA-DEB8-433C-B6E5-A552AE3DEB6A

P478

Q34662955-4E784EFB-6D4A-488A-9F11-3D7D0E99CC0A

P50

Q34662955-163017C5-429B-497E-BA3B-20006862F492

P577

Q34662955-63E56D55-E0DD-4740-B0ED-1C3233DED80D

P698

Q34662955-4E6121A0-949D-4DFC-8B0B-BD25F6E5C59B

P921

Q34662955-6F00A0FA-1904-42B6-BC8B-7D2AFC529302

Q34662955-8C8FA1D2-B81B-449A-BD7D-F13FADA0EE38

Q34662955-AAEFA909-6D7A-4A12-8621-A4FD76C95A04

P356

P1433

American Journal of Psychiatry

P1476

Six-week, double-blind, placeb ...... eficit hyperactivity disorder.

@en

P2093

Faraone SV

http://www.w3.org/2001/XMLSchema#string

Geller D

http://www.w3.org/2001/XMLSchema#string

Harding M

http://www.w3.org/2001/XMLSchema#string

Linehan C

http://www.w3.org/2001/XMLSchema#string

Prince J

http://www.w3.org/2001/XMLSchema#string

Schleifer D

http://www.w3.org/2001/XMLSchema#string

Spencer TJ

http://www.w3.org/2001/XMLSchema#string

Warburton R

http://www.w3.org/2001/XMLSchema#string

Wilens TE

http://www.w3.org/2001/XMLSchema#string

P304

1147-1153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1176/AJP.153.9.1147

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

153

http://www.w3.org/2001/XMLSchema#string

P50

P577

1996-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8780417

http://www.w3.org/2001/XMLSchema#string

P921

attention deficit hyperactivity disorder